|

White House warns Pfizer Covid-19 pill will not be widely available for months – FT

White House warns Pfizer Covid-19 pill will not be widely available for months – FT

The White House dims optimism over the Omicron cure after the US Food and Drug Administration (FDA) approved a pill from Pfizer to treat Covid-19.

“The White House has warned it will take more than six months to fulfill its initial order for Pfizer’s antiviral Covid-19 pill, as officials damped speculation the drug could immediately turn the tables on the pandemic,” said the Financial Times (FT)

Key quotes (from FT)

The US drugs regulator on Wednesday gave emergency authorization for the pill, called Paxlovid, to be used on people aged 12 and over with mild or moderate Covid-19 who are at risk of more severe symptoms.

But senior health advisers to President Joe Biden quickly warned that it would take months for the company to make and distribute all 10m treatment courses already on order.

Pfizer has said its pill cuts the risk of hospitalisation or death in Covid-19 patients by 89 percent.

It is likely to be especially important in the coming months because early lab tests show it continues to work against the fast-spreading Omicron variant, unlike some of the monoclonal antibody treatments already available.

FX reaction

Given the latest risk-on mood mainly driven by hopes of overcoming the South African covid variant, dubbed as Omicron, the news negatively affects the sentiment and should weigh on the recent gainers, namely Antipodeans and commodities.

Read: AUD/USD: Well-set for 0.7300 on firmer sentiment, US Durable Goods Orders, PCE Inflation eyed

Author

Anil Panchal

Anil Panchal

FXStreet

Anil Panchal has nearly 15 years of experience in tracking financial markets. With a keen interest in macroeconomics, Anil aptly tracks global news/updates and stays well-informed about the global financial moves and their implications.

More from Anil Panchal
Share:

Editor's Picks

AUD/USD crashes to January lows near 0.6650 after awful Aus jobs data

AUD/USD falls hard to its lowest since January, near 0.6650, in the Asian session on Thursday. The Australian Dollar (AUD) faces intense selling pressure against the US Dollar (USD) following weaker-than-expected Australian employment data, which ramped up RBA interest rate cut bets for next year. The weekly US Initial Jobless Claims report is due later on Thursday.


USD/JPY keeps its range near 159.50 despite hawkish BoJ Ueda

The Dollar rose against most major currencies but not the Yen, which is backed by intervention warnings near 160.00 and hawkish BoJ Ueda's commentary. USD/JPY is keeping its range around 159.50 in Asia on Thursday after a few sessions of small declines from a high just above 160.00. That high was its highest since early September.



Gold hits fresh lows near $3,680

Gold adds to the weekly pullback on Thursday, breaching below the $3,700 mark per troy ounce for the first time since September 2025. The precious metal’s persistent decline follows steady bets for further Fed tightening amid the solid performance of the US Dollar.

Crypto Today: Bitcoin, Ethereum, XRP rise ETF capital outflows

Cryptocurrency prices are gaining momentum on Thursday, albeit gradually. Bitcoin has risen from support near $62,000, edging higher toward $64,000. Altcoins broadly mirror Bitcoin’s gains, with Ethereum holding above $1,800 and Ripple trading slightly higher above $0.98.

Stocks rally in anticipation of $107 billion Anthropic IPO

AI stocks are gaining as strong demand for Anthropic's IPO lifts sentiment after recent selling. Anthropic is set to make history this week as the developer of the Claude artificial intelligence platform begins trading on the NASDAQ exchange under the ticker symbol ANT.

Gold's 14-month low looks mild next to Silver's fall from $121 to $44
Gold has lost a third of its value since January as traders bet on more Federal Reserve rate increases. Silver has lost nearly two-thirds, because the buyers still holding Gold up have no equivalent in the Silver market. Gold is trading below $3,700 for the first time since September 2025, a little more than a third under the record near $5,600 it set in late January.